Administration activities of 177Lu-PSMA were chosen cautiously in the treatment of advanced prostate cancer. The primary aim was to investigate the association between increased injected activities, and the calculated absorbed doses (AD). In this single center, retrospective analysis, patients with PSMA-avid metastatic...
Z. Ells, Linus Hempel, J. Ells et al.· EJNMMI Physics· 0 citations
177
Lu-PSMA radiopharmaceutical therapy shows favorable clinical responses for metastatic castration-resistant prostate cancer patients but may cause radiation-induced kidney damage due to specific and nonspecific activity accumulation. We evaluated the association between cumulative kidney absorbed doses and...
Z. Ells, Mu-Yu Wu, Linus Hempel et al.· EJNMMI Research· 0 citations
The phase 2 randomized LUNAR trial previously demonstrated that neoadjuvant 177Lu-PNT2002 before stereotactic body radiotherapy (SBRT) significantly improved progression-free survival (PFS) in patients with oligorecurrent hormone-sensitive prostate cancer (orHSPC). We report updated efficacy and safety outcomes with ex...
A. Kishan, H. Wilhalme, C. Felix et al.· European Urology· 0 citations
Fibroblast activation protein (FAP) has gained clinical interest as a target for imaging and therapy in a spectrum of oncologic diseases in recent years. Yet, FAP expression by activated fibroblasts is not specific to the tumor microenvironment but rather shows tight coupling to pathologic tissue remodeling, chronic in...
J. Enke, A. Barton, Koichiro Kimura et al.· AJR. American journal of roe...· 0 citations
BACKGROUND AND OBJECTIVE
Prostate-specific membrane-antigen positron emission tomography (PSMA-PET) detects distant metastases in more than half of patients with increasing prostate-specific antigen despite castrate levels of testosterone and high-risk nonmetastatic disease on conventional imaging. Here, we aim to eval...
C. Civan, M. Karpinski, C. Darr et al.· European Urology Focus· 0 citations
Background: The incremental value of PSMA PET/CT over multiparametric MRI (mpMRI) for selecting patients for prostate cancer focal therapy is undefined. Unlike lesion-detection studies, we evaluated whether PSMA PET/CT, mpMRI, and their combination correctly determine focal therapy eligibility when validated against wh...
I. Sonni, Zahra Mohammadigoldar, G. Furey et al.· medRxiv· 0 citations
Prostate-specific membrane antigen (PSMA)-targeted PET/CT (PSMA PET/CT) has become the first-line imaging modality used for staging and restaging prostate cancer. Its utility after minimally invasive focal therapy (high-intensity focused ultrasound, laser ablation, cryoablation) remains unclear. This study evaluated PS...
Mahbod Jafarvand, A. Farolfi, Riccardo Mei et al.· Journal of Nuclear Medicine· 0 citations
Background: Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) is increasingly used to characterize newly diagnosed prostate cancer on the assumption that uptake highlights aggressive disease. However, maximum standardized uptake value (SUVmax) varies widely across localized tumors. Recent gen...
G. M. Simo, P. Movva, J. Seo et al.· medRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.